US class action suit seeks to prevent delay of generic Gleevec

25-06-2015

US class action suit seeks to prevent delay of generic Gleevec

360b / Shutterstock.com

A group of individuals has reportedly launched a class action lawsuit against Novartis to stop it enforcing a so-called ‘pay-for-delay’ settlement agreement with generic drug maker Sun Pharma centring on leukaemia drug Gleevec (imatinib mesylate).


Gleevec, US District Court for the District of Massachusetts, Novartis, Sun Pharma, pay-for-delay

LSIPR